Xieqiao Yan

Peking University - Key Laboratory of Carcinogenesis and Translational Research

Beijing Cancer Hospital

SCHOLARLY PAPERS

2

DOWNLOADS

52

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

An Anti-CTLA-4 Antibody Ibi310 Alone or in Combination with Sintilimab in Patients with Advanced Melanoma or Urothelial Carcinoma: A Phase Ia/Ib Study

Number of pages: 27 Posted: 30 Nov 2023
Beijing Cancer Hospital, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Innovent Biologics, Inc., Innovent Biologics, Inc., Innovent Biologics, Inc., Peking University - Key Laboratory of Carcinogenesis and Translational Research and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 45 (896,170)

Abstract:

Loading...

CTLA-4, IBI310, Combination immunotherapy, Melanoma, Urothelial carcinoma

2.

Efficacy and Safety of Disitamab vedotin (RC48-ADC) in HER2-Negative Locally Advanced or Metastatic Urothelial Carcinoma: Results from a Phase 2 Clinical Study

Number of pages: 45 Posted: 11 Sep 2024
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, RemeGen, Ltd., Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research and Independent
Downloads 7 (1,307,098)

Abstract:

Loading...

Urothelial Carcinoma, Antibody Drug Conjugate, HER2-Negative, Disitamab Vedotin